Moderna shares slide amid Phase 3 cancer vaccine data chatter

MarketWatch reports Moderna’s stock fell about 7.4% at Monday’s open as investors digested chatter about Phase 3 data for intismeran, its experimental cancer vaccine with Merck. It says investors had “incredibly high” expectations. Barron’s reports the results were leaked and says Amgen showcased what it called “excellent” data for a small-cell lung cancer treatment.